26 C
Vientiane
Wednesday, October 15, 2025
spot_img
Home Blog Page 518

Hollyland Brings Global Creators to China for Cross-Cultural Tech and Creativity Tour

SHENZHEN, China, Aug. 25, 2025 /PRNewswire/ — As part of its WeConnect 2025 brand day celebration, Hollyland is bringing more than 30 global creators to China for a five-day tour focused on uniting cultures through technology and creativity. Over the past seven years, Hollyland has empowered over five million creators, helping them grow from storytellers to recognized influencers. This year’s celebration puts the spotlight on CONNECTION, using technology to bring people together and enable collaborations that transcend borders and language.

Hollyland Brings Global Creators to China for Cross-Cultural Tech and Creativity Tour
Hollyland Brings Global Creators to China for Cross-Cultural Tech and Creativity Tour

A Journey of Cultural Exchange and Technological Inspiration

From August 27-31, the five-day China Tour will open with Open Day at Hollyland’s Shenzhen headquarters, offering guests an immersive look into the city’s pulse of innovation. Visitors will discover Hollyland’s history and R&D strengths through hands-on livestream workshops and networking sessions with fellow creators.

Culture Day (August 28) will transport participants to the storied “8D magic city” of Chongqing, where they will immerse themselves in local traditions, savor authentic hotpot, and join a spirited “filming resource battle.”

On Panda Day (August 29), participants will enjoy giant panda encounters, teahouse traditions with cultural performances, and stunning skyline views from Raffles City Chongqing’s Exploration Deck, immersing themselves in the unique charm of Chongqing.

Creative Day (August 30) will offer an energetic deep dive into Chongqing’s famed “8D” streets, culminating in a dazzling drone show over the illuminated cityscape, balanced with moments of relaxation through traditional massage and spa experiences.

The journey will conclude with Celebration Day on August 31, where participants will compile a shared memory album, embark on a treasure hunt, cruise the river under the stars, and enjoy a farewell dinner against the backdrop of the city’s sparkling night view.

“Over the past decade, Hollyland has grown far beyond being just a provider of creative tools. We’ve become a trusted technology partner for millions of creators,” said Charon Liu, Brand Manager of Hollyland. “From our conversations with filmmakers and users worldwide, we’ve learned that the biggest challenges aren’t only about camera techniques or shooting skills. The WeConnect initiative was created to give our community, the users who have grown with us, more opportunities to share ideas, spark inspiration, and ensure every unique voice can cross boundaries and be heard around the world.”

Celebrating Worldwide Creativity through Sounds, Stories, and Collaboration

Launched on July 15, the Hollyland WeConnect 2025 celebration extends far beyond the China Tour. The Sound Museum project, running from July 28 to September 12, has gathered voice-based works from creators worldwide, transcending language and geography. More than 3,000 clips are already on display, alongside the Theme Song Lab, which transforms users’ stories into music. Three musicians have composed tracks based on these real accounts, with the public voting for the song that will become the event’s official theme.

The Hello World video contest invites creators to capture moments that unite people across cultures, blending tradition and technology. Through personal lenses, participants showcase authentic perspectives of their hometowns, cultures, and communities, adding to a growing mosaic of global stories.

The Hollyland Academy Special Version builds on the company’s international training and exchange program by introducing locally themed creative experiences. Participants can join culture-focused workshops, collaborate on projects, and compete for exclusive rewards, fostering an open and connected global creator network.

Trusted for its reliable technology and innovation-driven approach, Hollyland continues to bridge global creative communities through tools, ideas, and experiences. WeConnect 2025 once again brings technology and culture together, empowering creators to share, learn, and grow, while amplifying diverse voices and fostering meaningful connections to advance global creative collaboration.

For more information, please visit: https://www.hollyland.com/event/we-connect-2025.

YEEDI M14 PLUS: Clean Floors, Calm Mind, Wellness Ritual

Only YEEDI Offers Fresh Water Mopping, Every Time

SAN FRANCISCO, Aug. 25, 2025 /PRNewswire/ — In a world where calendars are packed, screens never sleep, and mental load runs high—especially for those balancing demanding careers and full lives—coming home to calm matters more than ever. Clean, orderly spaces aren’t a luxury; they’re a foundation for focus, rest, and emotional well‑being.

Today, the leading robot vacuum brand YEEDI introduces the YEEDI M14 PLUS again to the world, featuring the ground-breaking OZMO fresh water mopping system, to help reclaim that calm. Designed to lift the invisible weight of daily upkeep, M14 PLUS delivers effortless, whole‑home cleaning so hands are free, minds are clearer, and evenings feel like yours again. By pairing powerful performance with accessible pricing, YEEDI makes everything just as easy as possible.

YEEDI M14 PLUS
YEEDI M14 PLUS

Peace of Mind Starts from Truly Clean Floors

Recent studies show what many already feel: when your environment is clean, your mind follows. A tidy, hygienic space is closely linked to reduced stress, better focus, and improved emotional wellbeing. But in a life full of demands, maintaining that clarity at home can feel like one more item on a never-ending list.

The YEEDI M14 PLUS was designed to shift that dynamic. With every clean, it brings a quiet sense of control and calm—especially in those subtle moments, like when bare feet meet a freshly mopped floor. Whether your ritual of restoration includes yoga, meditation, reading, or simply unwinding in silence, the M14 PLUS clears the way—taking care of the one surface that connects everything: your floor.

And it does it all using only fresh, clean water—every single time—so your calm begins from the ground up.

“YEEDI believes that a truly clean home is essential to inner peace,” the brand states. “We created the M14 PLUS not just as a cleaning solution, but as a way to turn your living space into a restorative sanctuary—where technology quietly supports your wellbeing.”

No Dirty Water, No Residue, Just Freshness

Unlike traditional spinning or vibrating pads that recycle dirty water—leaving behind streaks, residue, and even unpleasant odors—the M14 PLUS offers something entirely different: true freshness with every pass. Co-developed with floorcare pioneer Tineco, its patented horizontal roller mop uses a closed-loop, 4-stage system that sprays, scrubs, rinses, and extracts in real time. No smears. No re-used water. Just visibly cleaner floors, powered by 200 RPM rotation and 4,000 Pa of consistent pressure.

It doesn’t just clean—it restores the purity of your space.

YEEDI M14 PLUS
YEEDI M14 PLUS

Thoughtfully Engineered for Effortless Calm

Beyond its mopping brilliance, the M14 PLUS is equipped with intelligent, quietly powerful features designed to remove friction from your daily rhythm:

  • ZeroTangle 3.0: Minimizes hair tangles and brush maintenance
  • Tru-Edge 2.0: Reaches corners and edges with seamless precision
  • AIVI 3D 3.0 Navigation: Learns your layout, navigates with grace
  • Space-saving OMNI Station: Compact, sleek, and fully self-cleaning

It’s a calm, consistent presence in your home—working quietly in the background to keep life flowing with more ease and clarity.

Reclaim Your Time. Restore Your Rhythm. Return to Calm.

YEEDI believes that clean floors are more than a visual upgrade—they are an emotional reset. With the M14 PLUS, every clean cycle becomes an act of care. Not just for your space, but for your time, your routines, and your inner calm.

YEEDI Roller Mop Series Now at All-Time Low Prices — Starting at Just $699

Starting today, all YEEDI roller mop models are available at their lowest prices in history — making now the perfect moment to invest in your home’s calm and cleanliness. Start your wellness ritual with a floor that feels as good as it looks.

About YEEDI

YEEDI is a cutting-edge service robot brand that embraces the concept of “Live Smart. Enjoy Life.” With constant upgrades, pioneering technology solutions are integrated into robotics for an enhanced consumer experience. Thus, consumers can enjoy a modern lifestyle with high standards of quality.

High-Trend International Group Announces Regained Compliance With the Minimum Bid Price Requirement of Nasdaq

SIGNAPORE, Aug. 25, 2025 /PRNewswire/ — High-Trend International Group (the “Registrant” or the “Company”) (NASDAQ: HTCO), a global ocean technology company announced that it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.

The Company had previously announced on June 30, 2025, that it was notified by Nasdaq on June 27, 2025 that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s ordinary shares had been below $1.00 per share for more than 30 consecutive business days. Pursuant to Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company had a compliance period of 180 calendar days, or until December 24, 2025, to regain compliance with Nasdaq’s minimum bid price requirement.

On August 22, 2025, Nasdaq provided confirmation to the Company that for the last 10 consecutive business days, from August 8, 2025 to August 21, 2025, the closing bid price of the Company’s ordinary shares had been $1.00 per share or greater, that the Company has regained compliance with Listing Rule 5550(a)(2) and that the matter is now closed.

Forward-Looking Statements

This current report on Form 6-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements can be also identified by terminology such as “may,” “might,” “could,” “will,” “aims,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements.

These forward-looking statements are based on our current assumptions, expectations and beliefs and involve substantial risks and uncertainties that may cause results, performance or achievement to materially differ from those expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to a number of risks. The reader should not place undue reliance on these forward-looking statements, as there can be no assurances that the plans, initiatives or expectations upon which they are based will occur. A detailed discussion of factors that could cause or contribute to such differences and other risks that affect our business is included in filings we make with the Commission from time to time, including our most recent report on Form 20-F, particularly under the heading “Risk Factors”.

 

Ambilight Collaborates with NIO to Bring Electrochromic Side Windows to the Launched All-New ES8

SHENZHEN, China, Aug. 25, 2025 /PRNewswire/ —  Ambilight, a leader in smart glass technology, is proud to announce its partnership with NIO, the premium smart electric vehicle company. The all-new NIO ES8, a full-size, all-scenario flagship SUV, features Ambilight’s Electrochromic (EC) Smart Dimming Side Windows as part of its cutting-edge design.

Ambilight Collaborates with NIO to Bring Electrochromic Side Windows to the Launched All-New ES8 Flagship SUV
Ambilight Collaborates with NIO to Bring Electrochromic Side Windows to the Launched All-New ES8 Flagship SUV

Electrochromic (EC) side windows are a new-generation automotive solution designed to intelligently adjust light transmittance, offering superior privacy protection, flexible brightness control and thermal insulation while enhancing comfort and a premium user experience.

The new ES8 offers a spacious cabin with diverse lighting requirements under varying driving conditions. By integrating Ambilight’s EC Smart Dimming Windows, NIO enhances both user experience and functionality, allowing passengers to enjoy a more adaptable and intelligent environment. The technology delivers a transmittance of down to 0.35% in its darkest state, offering effective privacy protection and solar control without compromising transparency or visibility.

EC side windows also provide exceptional protection by blocking up to 99.9% of ultraviolet rays and 97% of infrared rays, significantly reducing heat buildup caused by solar radiation. This not only helps maintain a comfortable cabin temperature but also protects the skin, offering year-round health benefits. In addition, the system supports four-zone independent control, three-level transparency adjustment, and one-touch switching, enabling a highly flexible and user-friendly lighting experience.

The company has consistently advanced the maturity and reliability of EC solutions, enabling large-scale adoption by automakers. Today, Ambilight is the only company worldwide capable of mass-producing both EC sunroofs and EC side windows.

With four years of EC innovation and four product generations, Ambilight’s technology has already been adopted by more than 20 vehicle models worldwide, serving over 100,000 users. This collaboration with NIO reinforces Ambilight’s position as the leading provider of smart glass solutions for the next era of intelligent vehicles.

Boxabl Bolsters Treasury with Acquisition of 10 Bitcoin

Initial Bitcoin Purchase Demonstrates Execution of Treasury Strategy Previously Announced in May

LAS VEGAS, Aug. 25, 2025 /PRNewswire/ — Boxabl Inc. (“Boxabl” or the “Company”), a leading innovator in modular home manufacturing, announces the acquisition of 10 Bitcoin (“BTC”) as part of its established treasury reserve strategy. This move underscores Boxabl’s commitment to diversifying its financial reserves with assets aligned to its long-term vision.

Boxabl first adopted its BTC treasury reserve strategy in May 2025, enabling the company to hold a portion of its assets in Bitcoin to hedge against inflation, diversify its portfolio, and preserve long-term value (Press Release). The 10 BTC were purchased at an average price of approximately $107,800 per BTC, reinforcing Boxabl’s financial position as it scales its operations and delivers affordable housing solutions globally.

“Integrating Bitcoin into our treasury reflects our forward-thinking financial strategy,” said Galiano Tiramani, Co-CEO of Boxabl. “This acquisition reinforces our confidence in Bitcoin’s long-term value and supports our mission to build a resilient and innovative company capable of navigating dynamic economic conditions.”

In parallel with its treasury initiatives, Boxabl recently announced that it has entered into a definitive merger agreement with FG Merger II Corp. (Nasdaq: FGMC), a special purpose acquisition company. The transaction is expected to result in Boxabl becoming a publicly traded company on Nasdaq under the ticker symbol “BXBL.” The proposed merger values Boxabl at approximately $3.5 billion and included no minimum cash conditions to close. See the Form 8-K filed on August 5th, 2025 with the Securities and Exchange Commission for additional information (https://www.sec.gov/ix?doc=/Archives/edgar/data/1816937/000110465925073950/tm2522586d1_8k.htm). For Important Information and Disclaimers Related to the Transaction Click Here: https://www.boxabl.com/disclosure

Boxabl continues to balance traditional assets with innovative investments—including Bitcoin—to support its operational goals, notably the production of its flagship Casita modular home and expansion into new markets. The company has raised over $230 million from more than 50,000 investors to date, further solidifying its financial foundation and positioning itself for long-term growth.

About BOXABL

BOXABL is a Las Vegas-based technology company dedicated to transforming the housing industry through innovative manufacturing and design. With a focus on affordability, sustainability, and scalability, BOXABL’s patented technology enables the mass production of high-quality, cost-effective homes. The company has attracted over 50,000 investors and raised more than $200 million to support its vision of addressing the global housing crisis.

For more information about BOXABL and its mission, visit www.boxabl.com.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding BOXABL’s board search, public company transition, and proposed business combination with a SPAC. These statements are subject to risks and uncertainties, and actual results may differ materially. For more information on these risks, please refer to BOXABL’s filings with the Securities and Exchange Commission.

Cryptocurrency and Treasury Strategy Risks

The acquisition and holding of cryptocurrency, such as Bitcoin, as part of a corporate treasury strategy introduces several significant risks that should be carefully considered and disclosed. Bitcoin and other digital assets are subject to extreme price volatility, which can materially impact the value of the company’s reserves and overall financial position. In addition, the regulatory landscape for cryptocurrencies remains uncertain and is subject to rapid change, potentially affecting the company’s ability to hold, transact, or account for these assets in the future. There are also operational and security risks associated with the custody and management of digital assets, including the potential for loss or theft due to cyberattacks or inadequate internal controls. Furthermore, accounting for cryptocurrency holdings may present challenges, as current standards may not fully address the unique characteristics of these assets, leading to potential inconsistencies in financial reporting.

Narwal Unveils the S30 Series Wet Dry Vacuum with Next-Level Cleaning Power

The S30 Series delivers powerful, maintenance-free cleaning for today’s busy households.

NEW YORK, Aug. 25, 2025 /PRNewswire/ — Narwal, a global leader in smart home cleaning technology, proudly announces the launch of its new flagship, the S30 Pro Wet Dry Vacuum, setting a new benchmark for effective and maintenance-free cleaning. Alongside it, Narwal introduces the Narwal S30, a more streamlined model that brings advanced performance to value-conscious households.

Narwal S30 Series Wet Dry Vacuum
Narwal S30 Series Wet Dry Vacuum

To elevate everyday cleaning, the S30 Series builds on the success of the S20 Pro with significant upgrades in performance, hygiene, and usability. It delivers up to 20,000Pa of powerful suction for a deeper clean across all floor types. Its enhanced self-cleaning and drying system reaches to 194°F, ensuring mop pads stay fresh and bacteria-free. A new auto hair cutting system prevents tangles, eliminating one of the most common pain points in vacuum maintenance. For added convenience, a disposable waste separation bag allows for hygienic, touch-free disposal. And with a 180° lie-flat design and 63° easy-turning angle, the S30 Series easily glides under furniture and into tight spaces—making whole-home cleaning more effortless than ever.

Deep Cleaning, Extended Coverage

The Narwal S30 Series delivers unparalleled cleaning performance with an impressive 20,000Pa suction power and 20N of downward mopping pressure—combining powerful vacuuming and effective scrubbing for a truly deep clean. It releases clean water in real time and immediately collects dirty water, ensuring that every wipe is done with fresh water for maximum hygiene and efficiency. Engineered for edge-to-edge precision, its unique Triple-Sided Edge Cleaning design reaches stubborn dirt along walls, baseboards, and tight edges that conventional vacuums often miss. For hard-to-reach spaces, the S30 Series features an ultra-flexible 180° flat-lying body and 63° turning angle, allowing it to glide effortlessly under sofas, around table legs, and into deep room corners with ease.

SGS and TÜV Certified Tangle-Free System:

The S30 Series features a SGS and TÜV certified Tangle-Free System designed to eliminate one of the most common frustrations for vacuum cleaners—hair tangles. The Dual Comb removes hair from the roller and guides it smoothly into the suction port, preventing tangles at the source. Exclusive to the S30 Pro, it is the first in the industry to feature a built-in blade in the base station that automatically cuts through tangled hair, ensuring uninterrupted cleaning even in homes with heavy shedding. A great fit for pet owners, the S30 Pro handles large volumes of fur and hair with ease—no clogs, no mess, no maintenance delays.

Truly Maintenance-Free Experience:

The S30 Series is engineered to deliver a truly maintenance-free cleaning experience, redefining convenience for the modern home. Its advanced base station heats water up to 194°F* for deep self-cleaning, while dual-direction brush rotation thoroughly cleans the roller mop from every angle—keeping each bristle fresh and ready for use. An innovative high-temperature ironing system gently presses and dries the roller mop, restoring its fluffiness and ensuring it remains soft, hygienic, and ready for deep cleaning. A disposable waste separation bag keeps dry and wet waste apart, allowing for clean, touch-free disposal—no dumping, no mess. The system also thoroughly dries internal tubing and the filter to minimize moisture buildup and prevent mold. For added freshness, a built-in deodorizing box helps neutralize odors inside the base station. Taking smart cleaning a step further, the S30 Pro features automatic detergent dispensing, accurately measuring and releasing the optimal amount of cleaning solution in real time—delivering precision and performance with every use.

Extended Runtime and User-Friendly Design:

The S30 Series combines extended runtime with intuitive, user-friendly design to elevate the cleaning experience. With up to 60 minutes* of runtime and a cleaning coverage of up to 4,300 square feet on a single charge, it easily handles large homes without interruption. Powered by AI DirtSense, the S30 Series intelligently detects dirt levels and adjusts its cleaning accordingly for optimal results. Users can also choose from five smart cleaning modes tailored to different floor types and cleaning needs—delivering precision, control, and convenience in every clean.

Availability and Pricing

The Narwal S30 Series is officially available starting today, with a limited-time launch window running to September 7, 2025. The S30 Pro carries a suggested retail price of $549.99, but will be offered at an exclusive launch price of $499.99 during this period. The S30 is priced at $449.99, with a special introductory offer of $399.99. Both models are available through Narwal’s official website and Amazon.

About Narwal

Narwal is dedicated to developing innovative products that transform daily life. Our range of solutions addresses common challenges, with a focus on understanding and meeting user needs through extensive R&D. This commitment has yielded industry-firsts like the Auto-washing mop, AI-powered DirtSense™, and the DualFlow Tangle-Free System. We obsess over every detail to ensure our products are both functional and aesthetically pleasing, aiming to blend design and performance for a better daily life. As a top-five global vacuum brand, Narwal serves over 3 million users across 30 countries, including North America, South Korea, Germany, and Australia. Our innovations have been honored with awards like the CES Innovation Awards, Edison Gold Award, and Time Magazine’s Best Inventions.

*The Narwal S30 Pro features high-temperature washing and drying at 194°F, while the Narwal S30 operates at 176°F for both functions.

*The Narwal S30 Pro offers up to 60 minutes of runtime on a single charge, while the Narwal S30 provides up to 55 minutes.

 

Keep Inc. Announces 2025 Interim Results

BEIJING, Aug. 25, 2025 /PRNewswire/ — Keep Inc. (“Keep” or the “Company”), the largest online fitness platform in China, today announced its unaudited interim results for the six months ended June 30, 2025.

First Half 2025 Financial Highlights

  • Total revenues were RMB821.8 million for the six months ended June 30, 2025, representing a 20.8% year-over-year decrease, which was primarily attributable to the strategic transformation with an all-out focus on AI, including proactive downsizing of non-core and less effective operations, as well as optimization of the product mix to enhance profitability.
  • Gross profit was RMB429.1 million in the first half of 2025, with gross profit margin at 52.2%, a 6.2 percentage point increase from 46.0% in the first half of 2024.
  • Adjusted net profit (non-IFRS measure) was RMB10.3 million, representing a turnaround from an adjusted net loss (non-IFRS measure) of RMB160.7 million in the first half of 2024.

First Half 2025 Operational Highlights

Six months ended June 30,

2025

2024

Average monthly active users (“MAU(s)“) (in thousands)

22,486

29,660

Average monthly revenues per MAU (in RMB)

6.1

5.8

Average monthly subscribing members (in thousands)

2,787

3,282

Membership penetration rate

12.4 %

11.1 %

Mr. Wang Ning, Chief Executive Officer of Keep Inc., commented, “2025 marks a pivotal chapter as we transform from a content-centric platform into an AI-powered, data-driven fitness agent. We anchored our strategic efforts on two key pillars in 2025: advancing AI-powered platform architectural transformation, and implementing profitability turnaround. For the first half of 2025, this two-pronged strategy has yielded solid progress, as we re-engineered AI fundamental architecture and launched foundational AI coaching capabilities. Concurrently, we reevaluated and optimized our self-branded fitness product portfolio to enhance margins, and optimized operational efficiency across sales channels and supply chain. These initiatives collectively drove a fundamental inflection point in achieving our first-ever adjusted net profit (Non-IFRS measure) turnaround for the first half of 2025. 

Building on this momentum, we roll out the pilot version of our first AI Koach Kaka. Since its launch, AI Koach Kaka has been accessible to all users, with limited usage available for non-members. AI Koach Kaka has showcased positive growth momentum, as evidenced by core AI daily active users surpassed 150,000 by the end of July 2025. Among its core functions, the dietary logging module has emerged as a high-frequency, essential-use scenario, further demonstrating the value and stickiness of our AI-powered coaching features.

Looking ahead, we will continue to pursue a strategy focused on gross margin improvement and operational efficiency to drive profit resilience, while capitalising on critical marketing windows to amplify product visibility and reignite business growth. We will firmly anchor our development path by advancing AI product innovation to breakthrough scale boundaries; fuel growth momentum for self-branded fitness products, altogether driving our long-term sustainable development.”

2025 Interim Financial Results

Revenues

Total revenues were RMB821.8 million for the six months ended June 30, 2025, representing a 20.8% decrease from RMB1,037.3 million for the six months ended June 30, 2024, which was mainly due to the decrease in revenues generated from self-branded fitness products and online membership and paid content.

Revenues from self-branded fitness products were RMB396.7 million for the six months ended June 30, 2025, representing a 20.9% decrease from RMB501.5 million for the six months ended June 30, 2024, which was mainly attributable to the scaled back of certain less effective and underperforming categories.

Revenues from online membership and paid content were RMB337.1 million for the six months ended June 30, 2025, representing a 22.9% decrease from RMB437.0 million for the six months ended June 30, 2024, mainly attributable to the decreased revenues from online sports events.

Revenues from advertising and others were RMB88.0 million for the six months ended June 30, 2025, representing a decrease of 11.0% from RMB98.9 million for the six months ended June 30, 2024, which was mainly attributable to the scaled back certain non-core business operations in 2024.

Cost of revenues

Cost of revenues was RMB392.7 million for the six months ended June 30, 2025, representing a decrease of 29.9% from RMB560.0 million for the six months ended June 30, 2024, which was in line with respective to the revenue trends during the period.

Cost of self-branded fitness products was RMB258.7 million for the six months ended June 30, 2025, representing a 24.7% decrease from RMB343.3 million for the six months ended June 30, 2024, which was mainly attributable to the decrease of cost of inventories sold due to the optimized product mix and supply chain performance.

Cost of online membership and paid content was RMB96.6 million for the six months ended June 30, 2025, representing a 31.2% decrease from RMB140.4 million for the six months ended June 30, 2024, which was mainly attributable to decreases of RMB25.4 million in costs associated with online sports events and RMB9.0 million in payment channel fees paid to third-party application stores and other payment channels, respectively, in correspondence with the decrease of related revenues.

Cost of advertising and others was RMB37.4 million for the six months ended June 30, 2025, representing a 51.0% decrease from RMB76.4 million for the six months ended June 30, 2024, which was mainly attributable to the decreases of: (i) RMB7.6 million in advertising production costs due to the optimized costs for offline advertising activities; and (ii) RMB7.6 million in outsourcing and other labour cost and RMB7.1 million in employee benefit costs, respectively, relating to the gradual phase-out of the Keepland business in 2024.

Gross profit and gross profit margin

Gross profit was RMB429.1 million for the six months ended June 30, 2025, representing a 10.1% decrease from RMB477.3 million for the six months ended June 30, 2024, which was mainly due to the decrease of revenues, partially offset by the decrease of cost of revenues.

Gross profit margin was 52.2% for the six months ended June 30, 2025, representing a 6.2 percentage points increase from 46.0% for the six months ended June 30, 2024, mainly due to the optimized business structure and related costs.

Gross profit margin of self-branded fitness products increased by 3.3 percentage points from 31.5% for the six months ended June 30, 2024 to 34.8% for the six months ended June 30, 2025, which was mainly driven by the refined product portfolio, rationalized pricing strategy and improved cost management.

Gross profit margin of online membership and paid content increased by 3.4 percentage points from 67.9% for the six months ended June 30, 2024 to 71.3% for the six months ended June 30, 2025, due to higher revenue contribution from online membership subscription and improved operational efficiency.

Gross profit margin of advertising and others increased by 34.7 percentage points from 22.8% for the six months ended June 30, 2024 to 57.5% for the six months ended June 30, 2025, primarily because we scaled down certain low gross margin business operations and optimized advertising production costs.

Fulfillment expenses

Fulfillment expenses were RMB43.8 million for the six months ended June 30, 2025, representing a 29.3% decrease from RMB61.9 million for the six months ended June 30, 2024, primarily due to a decrease in sale of self-branded fitness products and online sports events, as well as the further optimization of logistics and storage expenses.

Selling and marketing expenses

Selling and marketing expenses were RMB223.5 million for the six months ended June 30, 2025, representing a 30.9% decrease from RMB323.4 million for the six months ended June 30, 2024, primarily due to a decrease of RMB102.8 million in branding and marketing expenses due to the optimized promotion efficiency.

Administrative expenses

Administrative expenses were RMB82.8 million for the six months ended June 30, 2025, representing an 8.5% decrease from RMB90.5 million for the six months ended June 30, 2024, primarily attributable to a decrease of RMB24.9 million in professional fees, and partially offset by RMB19.1 million increase in administrative personnel costs (including related share-based compensation expenses). The increase was mainly due to the share-based compensation expenses increased by RMB26.5 million.

Research and development expenses

Research and development expenses were RMB 162.4 million for the six months ended June 30, 2025, representing a 17.0% decrease from RMB195.7 million for the six months ended June 30, 2024, primarily attributable to decreases of RMB18.7 million in research and development personnel costs (including related share-based compensation expenses), RMB5.6 million in depreciation and amortization of long-term assets and RMB3.8 million in outsourcing and other labor costs, respectively, primarily attribute to advanced workforce productivity, with AI technological enhancement.

Loss/profit for the period

As a result of the foregoing, the loss for the six months ended June 30, 2025 was RMB35.4 million, compared with a loss of RMB163.4 million for the six months ended June 30, 2024. The decrease of loss for the period was primarily attributable to the higher gross profit margin and reduced operating expenses. Adjusted net profit (non-IFRS measure) was RMB10.3 million for the six months ended June 30, 2025, compared with an adjusted net loss (non-IFRS measure) of RMB160.7 million for the six months ended June 30, 2024.

Non-IFRS Measures

Adjusted net profit (non-IFRS measures) was RMB10.3 million for the six months ended June 30, 2025, compared with an adjusted net loss (non-IFRS measures) of RMB160.7 million for the six months ended June 30, 2024.

Conference Call

The Company’s management will host an earnings conference call at 8:00 p.m. Beijing Time on August 25, 2025.

Participants who wish to join the call should follow the following method:

1)    Please click on the call link and complete the online registration form. Kindly register at least one working day before the event.
https://register-conf.media-server.com/register/BI553d63412e324eb782a509c4a6228f33

2)    Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.

3)    Select a method for joining the call

    1. Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
    2. Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number, and this function is only applicable for participants outside China.

4)    Please dial in 15 minutes before the call is scheduled to begin and provide the personal PIN to join the call.

Additionally, a live and archived webcast of the conference call will be available at https://ir.keep.com/en/news_events.php.

About Keep Inc.

Keep Inc. (HKEX Stock Code: 3650) is the largest online fitness platform in China in terms of MAUs and number of workout sessions completed by users in 2022, according to CIC. Keep offers a comprehensive fitness solution to help users achieve their fitness goals. On the Keep platform, extensive, professional, and premium fitness content with diverse activities and services are offered to encourage users to engage in daily exercise. Keep platform leverages AI technology to provide personalized workout programs incorporating recorded courses and interactive live streaming classes, dynamically customized to each user’s athletic levels, fitness goals, daily workout patterns and diet. Keep’s services seamlessly connect the physical and digital realms, spanning smart devices, workout equipment, athletic apparel and food to provide an immersive fitness experience.

For more information on Keep Inc., visit https://keep.com/.

Forward-looking Statements

This press release contains forward-looking statements relating to the business outlook, estimates of financial performance, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect and may not be realised in the future. Underlying these forward-looking statements are a lot of risks and uncertainties. In light of the risks and uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as representations by the board of directors of the Company or the Company that the plans and objectives will be achieved, and investors should not place undue reliance on such statements.

Non-IFRS Measures

To supplement our consolidated financial statements, which are presented in accordance with IFRS Accounting Standards as issued by the IASB, we also use adjusted net profit/(loss) as an additional financial measure, which is not required by, or presented in accordance with, IFRS Accounting Standards.

The Company’s management believe adjusted net profit/(loss) provides useful information to investors and others in understanding and evaluating our consolidated results of operations in the same manner as they help our management. However, our presentation of adjusted net profit/(loss) may not be comparable to similarly titled measures presented by other companies. The use of adjusted net profit/(loss) has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for an analysis of, our results of operations or financial condition as reported under IFRS Accounting Standards.

 

Consolidated Statement of Profit or Loss

 

Six months ended June 30,

2025

2024

RMB’000

RMB’000

(Unaudited)

(Unaudited)

Revenues

821,752

1,037,343

Cost of revenues

(392,672)

(560,021)

Gross profit

429,080

477,322

Fulfillment expenses

(43,786)

(61,921)

Selling and marketing expenses

(223,508)

(323,412)

Administrative expenses

(82,772)

(90,455)

Research and development expenses

(162,421)

(195,690)

Other income

27,668

3,809

Other gains, net

13,386

2,531

Operating loss

(42,353)

(187,816)

Finance income

7,555

25,834

Finance expenses

(631)

(1,371)

Finance income, net

6,924

24,463

Loss before income tax

(35,429)

(163,353)

Income tax expense

Loss for the period attributable to owners of the Company

(35,429)

(163,353)

Loss per share

    (expressed in RMB per share)

Basic

(0.08)

(0.35)

Diluted

(0.08)

(0.35)

 

 

 

Consolidated Statement of Financial Position

 

As at

June 30,

2025

As at

December 31,

2024

RMB’000

RMB’000

(Unaudited)

(Audited)

ASSETS

Noncurrent assets

Property and equipment

15,272

19,367

Right-of-use assets

23,987

34,657

Intangible assets

6,722

7,455

Financial assets at fair value through profit or loss

143,643

54,224

Financial assets at fair value through other comprehensive
income

20,000

Other non-current assets

53,635

54,164

263,259

169,867

Current assets

Inventories

123,862

136,736

Accounts and notes receivables

217,016

205,191

Prepayments and other current assets

172,846

195,486

Financial assets at fair value through profit or loss

465,953

433,009

Financial assets at amortized cost

16,422

Short-term time deposits

588

553

Restricted bank deposits

700

700

Cash and cash equivalents

533,991

764,260

1,531,378

1,735,935

Total assets

1,794,637

1,905,802

EQUITY

Equity attributable to owners of the Company

Share capital

168

168

Other reserves

8,234,785

8,204,827

Accumulated losses

(6,884,622)

(6,849,193)

Total equity

1,350,331

1,355,802


Consolidated Statement of Financial Position (Continued)

 

As at

June 30,

2025

As at

December 31,

2024

RMB’000

RMB’000

(Unaudited)

(Audited)

LIABILITIES

Noncurrent liabilities

Lease liabilities

8,334

17,462

Other non-current liability

5,639

8,334

23,101

Current liabilities

Accounts payable

156,549

149,240

Accrued expenses

151,872

246,152

Other current liabilities

35,130

42,076

Contract liabilities

75,850

71,790

Lease liabilities

16,571

17,641

435,972

526,899

Total liabilities

444,306

550,000

Total equity and liabilities

1,794,637

1,905,802

The following table reconciles our adjusted net profit/(loss) for the periods presented to the most directly comparable financial measure calculated and presented in accordance with IFRS Accounting Standards, which is loss for the six months ended June 30, 2025 and 2024:

 

Reconciliation of loss to adjusted net profit/(loss)

 

(Non-IFRS measure):

 

Six months ended June 30,

2025

2024

RMB’000

RMB’000

(Unaudited)

(Unaudited)

Loss for the period

(35,429)

(163,353)

Adjustment for:

Share-based compensation expenses

45,776

2,663

Adjusted net profit/(loss) for the period (Non-IFRS measure)

10,347

(160,690)

 

 

Henlius Keeps Steady Growth in H1 2025: Overseas Product Profits Soar 200%+, Innovation Fuels Global Reach

SHANGHAI, Aug. 25, 2025 /PRNewswire/ — Henlius (2696.HK) announced its 2025 interim results. In the first half of 2025, Henlius’ revenue reached about RMB2.8195 billion, representing an increase of 2.7% YoY. The gross profit of RMB2.1992 billion, up by 10.5% YoY, with a net profit reached RMB390.1 million. Operating cash flow reached RMB770.9 million, with an increase of 206.8% YoY, maintaining a steady positive inflow. Overseas products profits surged over 200%. Cash inflows from BD agreements exceeded RMB 1 billion, surging 280% YoY. As the overseas sales volume of commercialized products continues to rise, the company expects significant growth in overseas revenue and profits for the full year of 2025, with strong momentum likely to continue into 2026. The company remains committed to reinforcing its strategic focus on innovation and globalisation, actively advancing its end-to-end ecosystem to drive sustainable R&D growth with robust growth momentum. During the reporting period, the company invested RMB995.4 million in R&D, with an increase of 21.3% YoY in expensed R&D expenditures, prioritizing preclinical development of differentiated innovative molecules and construction of core innovation platforms.

Up to date, Henlius has 6 products launched in China, 4 approved for marketing in overseas markets, benefiting over 850,000 patients and reaching about 60 markets in Asia, Europe, Latin America, North America and Oceania. Meanwhile, the company is expanding its innovation pipeline in disease areas like oncology and autoimmune, advancing a differentiated portfolio of potential best-in-class (BIC) and first-in-class (FIC) candidates.

Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said “2025 is a pivotal year for Henlius. It is the year we shift into Globalisation 2.0 and step up the pace of innovation. We’re strengthening our end-to-end ecosystem and driving overseas revenue growth with global value at scale. Meanwhile, our core innovative products have achieved significant milestones, with the next-generation of high-potential molecules underway. Looking ahead, Henlius will adhere to patient-centricity and accelerate the delivery of superior innovative treatment solutions.”

Globalisation 2.0: actively advancing the end-to-end ecosystem

In the first half of 2025, Henlius’ global growth engine was in full swing, with global product revenue exceeding RMB2.5568 billion, representing an increase of 3.1% YoY.  Several products are accelerating their expansion into international markets, further improving patient access to essential therapies.

The company’s core innovative product serplulimab (trade name: HANSIZHUANG in China, Hetronifly® in Europe), the world’s first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of small cell lung cancer (SCLC), has recorded a global sales revenue of RMB597.7million during the reporting period. The overseas market expansion of serplulimab has been accelerated in the first half of 2025. It has received approvals in the Europe, Singapore, Malaysia, the United Kingdom and India for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Additionally, it has been approved in Indonesia and Thailand for the treatment of squamous non-small cell lung cancer (sqNSCLC). To date, serplulimab has been successfully approved in nearly 40 countries and regions, covering nearly half of the world’s population. A head-to-head bridging trial of serplulimab versus first-line standard of care atezolizumab for ES-SCLC in the U.S will also complete patient enrolment soon. The company plans to submit the Biologics License Application (BLA) to the FDA in the first half of 2026.

Henlius’ core breast cancer product HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), the “China-developed” mAb biosimilar approved in China, the EU, and the U.S., has recorded a global sales revenue of RMB1.4442 billion in the first half of 2025. During the reporting period, HANQUYOU (trastuzumab) was newly approved in countries including Mexico, bringing its cumulative approvals to over 50 countries and regions worldwide. In the HER2-positive breast cancer segment, Henlius has sequentially combined HANQUYOU (trastuzumab) with HANNAIJIA (neratinib) for extended adjuvant therapy to reduce recurrence risk in early-stage patients. Meanwhile, Henlius’ independently developed pertuzumab biosimilar, HLX11, has been accepted for marketing applications by regulatory agencies in China, the U.S., and Europe, and is anticipated to receive approval in th U.S. during the second half of 2025. Focusing on the breast cancer field, Henlius continues to build a comprehensive innovative product portfolio — candidates including Henlius’ HLX78 (lasofoxifene), an investigational novel endocrine therapy, the company’s novel epitope anti-HER2 mAb HLX22, the next-gen innovative HER2 ADC HLX87, the KAT6A/B inhibitor HLX97 with BIC potential, and the LIV-1 ADC HLX41 are accelerating their research progress.

In more disease fields, HLX04-O, a recombinant anti-VEGF humanised mAb injection jointly developed by the company and Essex, for the treatment of wet age-related macular degeneration (wAMD) has been accepted for the New Drug Application (NDA) in China in August 2025. This is the company’s first ophthalmic product submitted for marketing approval. The marketing applications for the denosumab biosimilar HLX14, intended for the treatment of osteoporosis and other indications, have been accepted in the U.S., EU, and Canada, with expected approvals in the second half of 2025.

In the first half of the 2025, Henlius accelerated the expansion of its core products into major global markets through strategic collaboration, further enhancing the company’s international influence and commercial capabilities. The company has entered into agreement with Abbott, granting it exclusive or semi-exclusive licenses for the development and commercialization of four self-developed biosimilars and one innovative biologic in 69 emerging markets including Asia and Latin America. The company has granted Dr. Reddy’s exclusive rights to HLX15, an anti-CD38 mAb, covering a total of 43 countries and regions across the U.S. and Europe. Besides, the company has also entered into an exclusive commercialization and semi-exclusive development collaboration with Lotus for the anti-PD-1 antibody serplulimab in multiple indications in South Korea. Additionally, the company has signed a licensing agreement with Sandoz, granting exclusive commercialization rights for HLX13, an CTLA-4 inhibitor, in the U.S., EU, Japan, Canada, and Australia.

In the first half of 2025, leveraging the advanced technologies and extensive resources, the company continued to reinforce its integrated biopharmaceutical platform including R&D, clinical trials, manufacturing, quality management, regulatory affairs, and commercialization. Up to date, the company has submitted over 800 drug registrations, and received more than 600 approvals, covering multiple countries and regions including China, the U.S., the EU, Canada, Indonesia and Japan. It has also conducted MRCTs in the U.S., the EU, Southeast Asia, Japan and other countries and regions, accelerating the globalisation process of its products. During the reporting period, Henlius continues to optimize its production operations and quality management system. The Songjiang Site has once again received the EU GMP Certificate, issued by the Federal Agency for Medicines and Health Products in Belgium, in July 2025. The completion of the Phase 1 of Songjiang Site II in August 2025 has further enhanced the company’s production capabilities. Up to now, the company has delivered over 1,150 batches of commercial GMP production, ensuring stable supply to countries and regions including China, Southeast Asia, Europe and Latin America. The company has successfully passed nearly 100 on-site inspections and audits conducted by global regulatory authorities and business partners, and has obtained GMP certifications from China, the EU, the U.S. and multiple PIC/S member countries, including Indonesia and Brazil.

Innovation breaks through the growth ceiling

In the first half of 2025, the company continued to advance its innovation-driven strategy, accelerating breakthroughs in cutting-edge technology platforms and driving robust growth in its innovative pipeline. Core products such as HLX43, HLX22, and serplulimab have each achieved significant global milestones.

HLX43 is a broad-spectrum anti-tumor ADC candidate targeting PD-L1 with BIC potential. The results of the phase 1 clinical trial of HLX43 have been first released at the 2025 ASCO Annual Meeting, demonstrating manageable safety profile and encouraging efficacy in various solid tumors especially in patients with NSCLC and thymic squamous cell carcinoma (TSCC). It shows encouraging efficacy in squamous and non-squamous NSCLC patients (sqNSCLC and nsqNSCLC), patients with or without EGFR mutation, patients with or without brain/liver metastasis, and PD-L1 positive or negative NSCLC patients, indicating its biomarker-independent antitumor potential. Previously, HLX43 has already been approved to conduct phase 2 MRCT in patients with non-small cell lung cancer (NSCLC) in China, the U.S., Japan and Australia, with first patients successfully dosed in both China and the U.S. Simultaneously, as the world’s first PD-L1 ADC indicated for thymic carcinoma (TC), HLX43 has received clinical trial approvals for the indication in the U.S. and other regions. A MRCT is planned to be initiated, aiming to fill the therapeutic gap in ADC treatment for this aggressive cancer type. In addition, the company is also accelerating the phase 2 clinical development of HLX43 in various solid tumors, including cervical cancer (CC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), nasopharyngeal cancer (NPC), colorectal cancer (CRC) and gastric/gastroesophageal junction cancer (GC/GEJC). Both monotherapy and combination therapies of HLX43 with other products are ongoing simultaneously to further exploit the synergistic effects of ADC-mediated cytotoxicity and immunotherapy-induced immune activation.

A phase 3 head-to-head clinical trial of Henlius’ novel enpitope anti-HER2 mAb HLX22 in combination with trastuzumab and chemotherapy comparing to current first-line standard of care therapy (trastuzumab + chemotherapy ± pembrolizumab) is steadily progressing. The first patient dosing has been completed in China, the U.S., Japan, Australia, and Korea, regardless of PD-L1 expression, with the aim of overcoming current limitations in first-line treatment of HER2-positive metastatic gastric cancer. Meanwhile, HLX22 has received Orphan Drug Designations from both the U.S Food and Drug Administration (FDA) and the European Commission (EC) in the first half the year for the treatment of gastric cancer, suggesting its significant therapeutic potential. Moreover, the updated data with over two years of follow-up from the phase 2 clinical study (HLX22-GC-201) evaluating HLX22 in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive advanced gastric cancer were presented at the 2025 ASCO Annual Meeting. The study data demonstrated that the efficacy benefit of HLX22 in HER2-positive gastric cancer remained stable with extended follow-up, outperforming previous data and providing solid data foundation for the subsequent phase 3 study.

Focusing on lung and gastrointestinal cancer, Henlius is continuously advancing the global clinical development of its self-developed innovative anti-PD-1 mAb serplulimab. In the field of lung cancers, the U.S. and Japanese bridging trial of serplulimab for SCLC, and a phase 3 MRCT of serplulimab combined with chemotherapy and radiotherapy for limited-stage SCLC (LS-SCLC) are currently underway in parallel to establish a solid foundation for future overseas regulatory registration, among which the phase 3 MRCT in LS-SCLC has completed the subject enrollment. In the field of gastrointestinal cancers, a phase 3 clinical trial of serplulimab plus chemotherapy as neoadjuvant/adjuvant therapy for gastric cancer, as well as the phase 3 MRCT (ASTRUM-015) of serplulimab in combination with bevacizumab and chemotherapy in first-line treatment of metastatic colorectal cancer (mCRC) have also completed subject enrollment. During the reporting period, a total of over 20 pivotal studies, investigator-initiated trials (IITs), and real-world studies (RWS) on serplulimab in the fields of lung cancer and gastrointestinal cancer were presented at major international academic conferences such as ASCO GI, ELCC, IGCC, ASCO, and WCLC, and were published in scientific journals including Cancer Immunology, Immunotherapy and Cancer Communications. Among them, the end-of-study analysis of the phase 3 clinical trial (ASTRUM-005) of serplulimab as the first line treatment for ES-SCLC has been first released at the 2025 ASCO Annual Meeting, featuring a four-year OS data of 21.9% and thus validating its long-term survival benefit.

While fully leveraging the value of its flagship molecules, the company is actively addressing unmet clinical needs and building an early-stage pipeline of high-potential candidates, creating strong momentum for sustainable, high-quality growth over the medium to long term. During the period, the company continued building and optimizing its competitive R&D platforms, including its ADC platform Hanjugator™ with independent intellectual property, T cell Engager (TCE) platforms, the one-stop drug discovery platform HAI Club, and the independently developed computing platform HAI PBD to enhance R&D capabilities. Meanwhile, building on its core antibody expertise, the company is making ongoing breakthroughs across target coverage and molecular diversity, accelerating multiple candidates toward clinical development, including the potential FIC human sialidase enzyme therapeutic HLX79, HLX701, the novel anti-CD47 SIRPα-Fc fusion protein with good safety profile, anti-PD-L1/VEGF bispecific antibody (BsAb) HLX37, potential BIC KAT6A/B small molecule inhibitor HLX97, TCE platform-derived DLL3xCD3xCD28 TCE HLX3901 and STEAP1xCD3xCD28 TCE HLX3902, Hanjugator™-based EGFRxcMET ADC HLX48, and potential FIC B7H3-sialidase enzyme HLX316.

Looking ahead, Henlius will remain committed to its patient-centric mission, accelerate global expansion, drive the efficient implementation of innovation outcomes, and continuously enhance its global product supply as well as quality systems, aiming to bring more high-quality, affordable innovative treatment options to patients worldwide.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 6 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company’s launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.